Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin With or Without Intensive Exercise in Type 2 Diabetes
jRCTs071180050Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Change in fat free mass at 24 weeks. Started Jul 2016; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs071180050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180050.